Opportunities & Risks in the Kenyan Pharmaceutical and Healthcare Sector

HTML clipboard

The Kenya Pharmaceuticals and Healthcare Report Independent 5-year pharmaceutical and healthcare industry forecasts for Kenya. Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Kenyan pharmaceutical and healthcare industry. Competitive intelligence, Kenyan pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Kenyan market. ( http://www.bharatbook.com/Market-Research-Reports/Pharmaceuticals-Healthcare-Report-Kenya.html ) The Kenya Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments. Kenya Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Kenyan pharmaceutical and healthcare industry. Key Benefits of Report : * Benchmark Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Kenya to test other views – a key input for successful budgeting and strategic business planning in the Kenyan pharmaceutical and healthcare market. * Target Business Opportunities & Risks in the Kenyan Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kenya . * Exploit The Latest Competitive Kenyan Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Kenya . Coverage  : Executive Summary & Industry SWOT An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with Economic and Business Environment SWOTS, give a complete overview of market climate. Market Summary Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market. Regulatory Regime Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market. Industry Developments Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation. 5-Year Industry Forecast : 5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including: * Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp * Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system * OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals) * Generics market (US$bn)/ as % of total market * Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population Forecasts based on bespoke economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

Contact us at :Bharat Book BureauTel: +91 22 27578668Fax: +91 22 27579131Email: info@bharatbook.com Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com

Powered By Rxid.com

Tags: demand forecast, Drugs, Healthcare, kenya, market forecast, market growth, market leaders, market report, market research, market share, Market., Pharmaceutical, Report, Research
Posted in Pharmaceutical | No Comments »

Direct to Consumer (DTC) Advertising in Pharmaceuticals

Direct to Consumer (DTC) Advertising in Pharmaceuticals – Current and Future Market Outlook, Regulatory Landscape and Case Studies

This report provides key data, information and analysis of the major issues affecting the stakeholders of the DTC advertising market in the US and Europe. It discusses the major changes that have been observed after the relaxation of rules over DTC advertising by the FDA in 1997. The report also covers the issues specific to the European market as well where branded DTC advertising is banned. The report provides a comprehensive view of some of the best examples of DTC advertising along with the analysis covering reasons for such success. The report also provides a detailed analysis of some of the failed examples along with the key learnings from the same. It also provides an insight into the government regulations in the US and Europe for DTC advertisements and their implications on the marketing strategies of the pharmaceutical companies. The report provides a detailed explanation of some of the major reasons behind recent developments in the pharmaceutical DTC advertising landscape. At the end, the report touches upon some of the major trends that are likely to shape the future landscape for the DTC market in the US and Europe. ( http://www.bharatbook.com/detail.asp?id=126915&rt=Direct-to-Consumer-DTCAdvertising-in-Pharmaceuticals-Current-and-Future-Market-Outlook-Regulatory-Landscape-and-Case-Studies.html )European Commission Proposal on Allowing Restricted DTC Advertising Brings Hope to the Pharmaceutical IndustryWhile branded DTC advertising is banned in Europe, over the past few years, bodies including the EC (European Commission), European Council and Council of Ministers have been softening their approach towards the pharmaceutical industry. Although the effort to relax the DTC advertising ban in 2002 for diseases such as AIDS, diabetes and asthma failed under public pressure, the recent proposal by the EC to allow restricted DTC advertising brings a new hope to the industry. In January 2008, the EC proposed to allow pharmaceutical companies to provide “objective” and non-promotional information to patients about their drugs in newspapers and websites. However, the proposal has already received resistance from various consumer advocacy groups across Europe expressing concern regarding the credibility of the pharmaceutical industry to provide clear and unbiased information about the drugs. There is also concern regarding the unclear definition of the term “objective information” which could be misused by the pharmaceutical industry. Thus, although the proposal would take some years to get legislated, it is expected to bring better prospects for the European pharmaceutical industry, if implemented.Integrated and Personalized Advertising Will Dominate the Future DTCA Landscape with Emergence of New and Better Media Channels to Reach PatientsWith the entry of new channels to reach to consumers, pharmaceutical companies have been developing advertising strategies that use a mix of all these channels in order to maximize the benefits of such marketing effort. Particularly, the increasing popularity of internet as an information source for patients has prompted the pharmaceutical companies to provide detailed information about the drug on internet websites and use the traditional media to divert patients to such websites. Such integrated marketing attempts to gain a double advantage through traditional media’s ability to reach the masses and the internet’s ability to provide more organized, detailed and, in some cases, personalized information to the patients. The periodic nature of television and print advertisements constantly reminds the patients about the medicine and helps in increasing patient compliance. Constant patient assistance through the patient support programs of pharmaceutical companies complements the traditional media based marketing efforts. Pharmaceutical Industry’s DTC (Direct-to-Customer) Advertising Expenditure would continue to Decline in FutureDTC advertising expenditure has decreased by more than 20% in the last two years after reaching its peak in 2006. Economic pressures, over and above, the global financial meltdown have resulted in a tighter budgetary situation for the pharmaceutical industry. These pressures have arisen from rapidly disappearing blockbuster drugs and decreasing R&D productivity. Tightening regulations and stringent requirements of the regulatory agencies in the US and Europe have also made the DTC landscape tough for the pharmaceutical companies. Besides the adverse conditions, the expenditure has also gone down due to increase in efficiencies due to shift towards more cost- 

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=126915&rt=Direct-to-Consumer-DTCAdvertising-in-Pharmaceuticals-Current-and-Future-Market-Outlook-Regulatory-Landscape-and-Case-Studies.html OrContact us at :Bharat Book BureauTel: +91 22 27578668Fax: +91 22 27579131Email: info@bharatbook.com Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com Follow us on twitter: http://twitter.com/3bbharatbook

Powered By Rxid.com

Tags: demand forecast, dtc, market forecast, market growth, market leaders, market report, market research, market share, Market., Pharmaceutical, Report, Research
Posted in Pharmaceutical | No Comments »

Direct to Consumer (DTC) Advertising in Pharmaceuticals

Direct to Consumer (DTC) Advertising in Pharmaceuticals – Current and Future Market Outlook, Regulatory Landscape and Case Studies

This report provides key data, information and analysis of the major issues affecting the stakeholders of the DTC advertising market in the US and Europe. It discusses the major changes that have been observed after the relaxation of rules over DTC advertising by the FDA in 1997. The report also covers the issues specific to the European market as well where branded DTC advertising is banned. The report provides a comprehensive view of some of the best examples of DTC advertising along with the analysis covering reasons for such success. The report also provides a detailed analysis of some of the failed examples along with the key learnings from the same. It also provides an insight into the government regulations in the US and Europe for DTC advertisements and their implications on the marketing strategies of the pharmaceutical companies. The report provides a detailed explanation of some of the major reasons behind recent developments in the pharmaceutical DTC advertising landscape. At the end, the report touches upon some of the major trends that are likely to shape the future landscape for the DTC market in the US and Europe. ( http://www.bharatbook.com/detail.asp?id=126915&rt=Direct-to-Consumer-DTCAdvertising-in-Pharmaceuticals-Current-and-Future-Market-Outlook-Regulatory-Landscape-and-Case-Studies.html )European Commission Proposal on Allowing Restricted DTC Advertising Brings Hope to the Pharmaceutical IndustryWhile branded DTC advertising is banned in Europe, over the past few years, bodies including the EC (European Commission), European Council and Council of Ministers have been softening their approach towards the pharmaceutical industry. Although the effort to relax the DTC advertising ban in 2002 for diseases such as AIDS, diabetes and asthma failed under public pressure, the recent proposal by the EC to allow restricted DTC advertising brings a new hope to the industry. In January 2008, the EC proposed to allow pharmaceutical companies to provide “objective” and non-promotional information to patients about their drugs in newspapers and websites. However, the proposal has already received resistance from various consumer advocacy groups across Europe expressing concern regarding the credibility of the pharmaceutical industry to provide clear and unbiased information about the drugs. There is also concern regarding the unclear definition of the term “objective information” which could be misused by the pharmaceutical industry. Thus, although the proposal would take some years to get legislated, it is expected to bring better prospects for the European pharmaceutical industry, if implemented.Integrated and Personalized Advertising Will Dominate the Future DTCA Landscape with Emergence of New and Better Media Channels to Reach PatientsWith the entry of new channels to reach to consumers, pharmaceutical companies have been developing advertising strategies that use a mix of all these channels in order to maximize the benefits of such marketing effort. Particularly, the increasing popularity of internet as an information source for patients has prompted the pharmaceutical companies to provide detailed information about the drug on internet websites and use the traditional media to divert patients to such websites. Such integrated marketing attempts to gain a double advantage through traditional media’s ability to reach the masses and the internet’s ability to provide more organized, detailed and, in some cases, personalized information to the patients. The periodic nature of television and print advertisements constantly reminds the patients about the medicine and helps in increasing patient compliance. Constant patient assistance through the patient support programs of pharmaceutical companies complements the traditional media based marketing efforts. Pharmaceutical Industry’s DTC (Direct-to-Customer) Advertising Expenditure would continue to Decline in FutureDTC advertising expenditure has decreased by more than 20% in the last two years after reaching its peak in 2006. Economic pressures, over and above, the global financial meltdown have resulted in a tighter budgetary situation for the pharmaceutical industry. These pressures have arisen from rapidly disappearing blockbuster drugs and decreasing R&D productivity. Tightening regulations and stringent requirements of the regulatory agencies in the US and Europe have also made the DTC landscape tough for the pharmaceutical companies. Besides the adverse conditions, the expenditure has also gone down due to increase in efficiencies due to shift towards more cost- 

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=126915&rt=Direct-to-Consumer-DTCAdvertising-in-Pharmaceuticals-Current-and-Future-Market-Outlook-Regulatory-Landscape-and-Case-Studies.html OrContact us at :Bharat Book BureauTel: +91 22 27578668Fax: +91 22 27579131Email: info@bharatbook.com Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com Follow us on twitter: http://twitter.com/3bbharatbook

Powered By Rxid.com

Tags: demand forecast, dtc, market forecast, market growth, market leaders, market report, market research, market share, Market., Pharmaceutical, Report, Research
Posted in Pharmaceutical | No Comments »

Global Pharmaceutical Market Forecast

Global Pharmaceutical Market Forecast to 2012 The global pharmaceutical market is expected to earn over a trillion dollar in revenues by 2012 and according to “Global Pharmaceutical Market Forecast to 2012”, our new research report, the market will witness a number of changes impacting its course of growth. These include the shift of growth from the developed markets to the emerging ones, increasing focus on biotech-based drugs, fewer new drug approvals, and a strong growth in the prevalence of generics. ( http://www.bharatbook.com/Market-Research-Reports/Global-Pharmaceutical-Market-Forecast-to-2012.html ) This report, an updated and far more exhaustive and analytical version of our popular 2006 study, provides a comprehensive analysis of every major pharmaceutical market worldwide. Thirty-four major pharmaceutical markets from North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. Factual insight, supplemented with statistical overview on the past, present and future, together with statistics and analysis pertaining to market size, growth, segmentation, government policies, healthcare indicators, key players, health coverage, new developments and future prospects has been provided for each market. “Global Pharmaceutical Market Forecast to 2012” acts as a valuable tool for pharmaceutical manufactures/investors/consultants who are studying the global pharmaceutical market as it helps in identifying and analyzing market opportunities that will suit their business needs and profiles. Key Research Findings § Growing at a CAGR of around 8%, the global pharmaceutical market is forecasted to reach US$ 1043.4 Billion in 2012. § North America remains the largest pharmaceutical market constituting 42.8% of the global sales in 2007. Growth in the region is however expected to slow down in near future owing to patent expiration of key drugs and increased prevalence of generics. § In Europe, growth in the top five markets is expected to remain sluggish in next five years. Emerging markets in Central and Eastern Europe is however expected to drive growth in future. § A large untapped population and strong economic growth in major countries is expected to make Asia-Pacific the most lucrative pharmaceutical market in future. § Growth in the Latin American markets is expected to be strong with Brazil and Mexico amongst the most emerging pharmaceutical markets in the world. § Dwindling drug pipelines and patent expiration of a number of blockbuster drugs may challenge the growth of global pharmaceutical market in future. Key Players Discussed in the Report This section provides the overview, key facts, strengths and weaknesses, and financial information of prominent players in the global pharmaceutical market like Pfizer Inc, Sanofi-Aventis, GlaxoSmithKline Plc and AstraZeneca Plc. Key Issues and Facts Analyzed in the Report § What are the emerging trends in the global pharmaceutical sector? § What are the future prospects of the pharmaceutical industry in various regions across the world? § What opportunities exist for the industry? § What challenges are being faced by the industry? § Who are the key players in the global pharmaceutical market? To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/Market-Research-Reports/Global-Pharmaceutical-Market-Forecast-to-2012.html Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: info@bharatbook.com Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com Follow us on twitter: http://twitter.com/3bbharatbook

Powered By Rxid.com

Tags: demand forecast, generics, market forecast, market growth, market leaders, market report, market share, market size, Market., Medical, Pharmaceutical, Report, Research
Posted in Pharmaceutical | No Comments »

Research And Development Of Pharmaceutical Industry Market

Pharmaceutical Industry Market Review Report ( http://www.bharatbook.com/Market-Research-Reports/Pharmaceutical-Industry-Market-Review.html ) which gives the information about the growth of Pharmaceutical Industry Market.  The total UK market for pharmaceuticals was worth an estimated £13.65bn in 2007. Prescription-only medicines accounted for most of this figure, with a smaller share being taken by over-the-counter (OTC) pharmaceuticals.  The UK is home to the most important pharmaceutical industry in Europe in terms of development and marketing. In 2006, the industry exported £13.8bn worth of medicines and showed a trade surplus of £4.3bn. The UK market is also one of the most cost-effective in Europe and, arguably, the world. Since 2005, the introduction of a new Pharmaceutical Price Regulation Scheme (PPRS) and the wider use of generic products have brought about a reduction in per capita expenditure on medicines by the NHS. Plans to introduce more value-based pricing could lead to even greater control over a drug’s long-term future within the Health Service than is currently the case. The National Institute for Health and Clinical Excellence (NICE) recently approved a pay-for-performance contract for a new treatment, Velcade, in a departure from the unit pricing model traditionally used in the market.  Greater analysis of the costs and benefits of the medicines used by the NHS is likely to take place in the future, but demand for pharmaceuticals continues apace. The number of prescriptions written in the UK is rising year-on-year and, since the UK has an ageing population, this trend looks set to continue. The most important therapeutic areas are likely to remain those related to age, such as cardiovascular disease and cancer. Demand for more effective treatments for neurological problems such as Alzheimer’s disease and psychiatric conditions is also likely to intensify.  The Government would like to place a greater emphasis on self-care — a strategy obviously supported by the OTC sector. Growth in sales of OTC medicines has been sluggish in recent years, and a fiercely competitive retail environment, creating downward pressure on prices, is likely to remain a feature of the UK market. As long as exemption from prescription charges remains so widespread, it is difficult to find ways of encouraging consumers to self-medicate. However, the research carried out for this report suggests that affluent consumers aged 25 to 54 are the most promising market.  The global market for pharmaceuticals is likely to continue to grow as developing countries demand higher standards of healthcare. However, the focus on cost control in major markets is likely to be sustained, and this will be reflected in the way that drugs are marketed, and also at the level of research and development (R&D). It may be that only the most visibly cost-effective treatments will survive. Nevertheless, the market will continue to be driven by demand for better treatments for the most pernicious diseases, and this augurs well for the UK pharmaceutical industry.  For more information please visit : http://www.bharatbook.com/Market-Research/Pharmaceuticals-Healthcare.html  Or  Contact us at:  Bharat Book Bureau Tel: +91 22 27578668  Fax: +91 22 27579131 Email: info@bharatbook.com  Website: www.bharatbook.com

Powered By Rxid.com

Tags: demand forecast, Industry., market forecast, market growth, market leaders, market share, market size, Market., medecine, Pharmaceutical, Report, Research
Posted in Pharmaceutical | No Comments »